Videos

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, who discussed recent treatment advancements and FDA approvals.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

Patients with prostate cancer may have an inherited or acquired BRCA mutation, and both can have treatment implications, an expert said.

Prehabilitation can help patients become eligible for certain cancer treatments, or also help them recover from therapies, while also improving their overall health and fitness, an expert explained.

With multiple therapies available for patients with myeloma, there are some considerations that patients should discuss with their clinicians before choosing which one is right for them, an expert said.

Wearable fitness devices can offer valuable insights for patients with cancer and the doctors treating them.

Artificial intelligence platforms such as ChatGPT are offering patients a more personal and conversational way to research their cancer, an expert said.

In conjunction with Cancer Champions, CURE® recently hosted the “Educated Patient® Webinar: An Overview of Diet and Exercise in Cancer Care."

In patients with cancer, clonal hematopoiesis was associated with cardiac toxicity and in increased risk of death due to heart conditions.

Patients with cancer should always let their clinical team know if they are experiencing any new symptoms or concerns.

Join CURE® for an Educated Patient® Webinar to hear from an expert panel of health care professionals and advocates who will discuss topics for patients, survivors, and caregivers including individualized care for GIST, recent updates to the NCCN guidelines, and general education on advanced GIST.

Multiple considerations must be made when determining cancer treatment regimens amid the ongoing chemotherapy shortage, explained an oncologist.

Therapies that target specific characteristics on kidney cancer cells are showing promise in the space, an expert explained.

With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.

Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.

Patients being treated for a myeloproliferative neoplasm should be open with their care team about any side effects they experience, an expert said.

Kim Stuck credits her cannabis use to the fact that she maintained her weight, was able to work out and was not in pain during breast cancer treatment.

Singer-songwriter Andrew McMahon is not the same person he was before his leukemia diagnosis, and that’s OK, he said.

It is essential for patients to live a healthy lifestyle while undergoing treatment for multiple myeloma, an expert said.

An expert discusses the ongoing SPARK trial for KRASG12-mutant non-small cell lung cancer, and what she hopes for the future of this patient population.

Watch Dr. Rami Komrokji and Dr. John O. Mascarenhas answer questions about myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. John O. Mascarenhas, from Icahn School of Medicine, discuss novel therapies in myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Rami Komrokji, from Moffitt Cancer Center, discuss risk stratification and management of myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch Dr. Nikolai Podoltsev, Dr. Jerry Spivak and Amy Lane answer questions about polycythemia vera during the CURE® Educated Patient® MPN Summit.

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed.

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.